As reported by FiercePharma, the global pharmaceutical company, Sanofi-Aventis has confirmed their alliance with Japanese pharmaceutical company Nicho-iko. The joint venture signals the company’s interest in capturing part of the Japanese generics market.
Sanofi is set to own 51 per cent of the joint venture and as part of the deal, they will buy a 4.66 per cent stake in Nichi-iko for $48 million.
The first step in this joint venture will see Nichi-iko taking over the marketing and distribution of Sanofi’s sleep drug Amoban.
Looking for a job in the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.